Abstract 6000 Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial. Li Zhang, Yunpeng Yang, Song Qu, Jin-Gao Li,…

Abstract LBA2 JUPITER-02: Randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). Rui-hua Xu, Hai-Qiang Mai,…

Abstract 4500 Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. Brian I. Rini, Elizabeth…

Abstract 9006 Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. Joshua Bauml, Byoung Chul…

Abstract 8005 IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Heather…

Abstract 6003 Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial. Jun Ma, Yu-Pei Chen, Ying Sun, Qin Zhou, Kun-Yu Yang, Feng…

Abstract 500 Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial. Josephine Lopes Cardozo, Caroline Drukker, Marjanka Schmidt, Laura van ’t Veer, Annuska Glas, Anke Witteveen,…

Abstract LBA1 OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. Andrew Tutt,…

Abstract 9001 Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA…

Abstract 9000 First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update…